Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to $4.0 million.

  • Karyopharm Therapeutics' Accounts Payables fell 2161.74% to $4.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.0 million, marking a year-over-year decrease of 2161.74%. This contributed to the annual value of $4.0 million for FY2025, which is 2161.74% down from last year.
  • As of Q4 2025, Karyopharm Therapeutics' Accounts Payables stood at $4.0 million, which was down 2161.74% from $5.4 million recorded in Q3 2025.
  • Over the past 5 years, Karyopharm Therapeutics' Accounts Payables peaked at $9.0 million during Q1 2023, and registered a low of $813000.0 during Q3 2022.
  • Over the past 5 years, Karyopharm Therapeutics' median Accounts Payables value was $2.9 million (recorded in 2021), while the average stood at $3.4 million.
  • Per our database at Business Quant, Karyopharm Therapeutics' Accounts Payables tumbled by 6397.75% in 2021 and then skyrocketed by 51325.56% in 2024.
  • Karyopharm Therapeutics' Accounts Payables (Quarter) stood at $1.6 million in 2021, then surged by 72.99% to $2.8 million in 2022, then grew by 12.62% to $3.1 million in 2023, then soared by 63.53% to $5.1 million in 2024, then dropped by 21.62% to $4.0 million in 2025.
  • Its Accounts Payables stands at $4.0 million for Q4 2025, versus $5.4 million for Q3 2025 and $2.6 million for Q2 2025.